Jordan Johnson, Founder and Principal at Bridge Oncology and Legal Data Expert, shared on LinkedIn:
“Policy work doesn’t end when the Proposed Rule is published. In many ways, that’s when the real work begins.
Over the past few days, we’ve received numerous questions regarding the proposed national reimbursement for proton therapy in the CY 2027 Medicare Physician Fee Schedule and if that is what Bridge wanted (definitely not). (Apparently there was twisting of words from our Newsletter)
Bridge was spot on in the methodology. CMS just needs to re-math in progress.
To clarify, Bridge Oncology‘s proposal to CMS focused on creating a transparent, nationally consistent payment methodology – not the approximately $765 reimbursement that later appeared after CMS updated Addendum B following the initial release of the Proposed Rule.
Our original framework and what was modeled and communicated illustrated national payment rates north of $1050, while still achieving CMS’s objective of payment standardization and site neutrality.
Bridge Oncology is actively working with stakeholders and CMS to address the proposed code values and provide additional analysis supporting appropriate reimbursement that reflects the complexity and resources required to deliver proton therapy.
We appreciate everyone who has reached out with thoughtful questions and constructive dialogue. We’ll continue to share transparent updates as this process moves forward and expect to have additional information soon.
To those who chose to publicly attribute (only a handful of gas lighters) the proposed reimbursement reductions to Bridge Oncology without first reaching out, reviewing our proposal, or understanding the timeline of events, we simply encourage your professionalism, motives, and agendas.
Bridge Oncology reads like a billboard!
In healthcare policy, credibility is built on diligence, transparency, and collaboration – not speculation. The oncology community deserves better than conclusions drawn without first seeking the truth or being driven by the need for credit, position, or justification.
The goal remains the same: protect patient access, support sustainable proton therapy programs, and help CMS develop reimbursement policies that are both equitable and data-driven.
Even crazier our work has been free….Commitment through Action”
Other articles about Jordan Johnson on OncoDaily.